According to an analysis of data from the Régie de l’assurance maladie du Québec (RAMQ), Johnson & Johnson's Remicade has steadily lost market share among patients enrolled in the province's public drug program, as reported in the Financial Post.
RAMQ had stopped covering Remicade, also known as infliximab, for some new patients in February 2017, in favor of biosimilar versions, mainly Pfizer's Inflectra.
However, while a Quebec court earlier this year ordered it to resume coverage, this has not reversed Pfizer’s gains, the news source said.
By August, 13.4% of 2164 patients were on Renflexis, Merck & Co.'s biosimilar version of Remicade, with the rest on Pfizer's biosimilar.
Biosimilar market share for infliximab rose to 11.4% in January 2019, from 0.7% in February 2017, according to the analysis of RAMQ data.
To read more NewsPoints articles, click here.